Last reviewed · How we verify

NCT05871073

Dexamethasone as Adjuvant to Ropivacaine in Wound Infiltration for Postoperative Analgesia Following Spinal Surgery

Completed Phase 4 Last updated 23 May 2023
What this trial tests

Phase 4 trial testing Ropivacaine 0.75% Injectable Solution in Lumbar Spinal Stenosis in 60 participants. Completed in 5 March 2023.

Timeline
1 January 2023
Primary endpoint
4 February 2023
5 March 2023

Quick facts

Lead sponsorUniversity Hospital Fattouma Bourguiba
PhasePhase 4
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingtriple
Primary purposetreatment
Enrollment60
Start date1 January 2023
Primary completion4 February 2023
Estimated completion5 March 2023
Sites1 location across Tunisia

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital Fattouma Bourguiba

Who can join

Adults 18 to 90, any sex, with Lumbar Spinal Stenosis or Lumbar Disc Herniation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Introduction: Improving postoperative pain management after spinal surgery is a significant challenge for surgeons and anesthesiologists. Pain following spinal surgery, can lead to significant morbidity, limit early mobility, and increase the risk of chronic pain. This trial examines the analgesic effects of dexamethasone as an adjuvant to ropivacaine in wound infiltration after lumbar surgery. Methods: In this study, we randomly assigned sixty patients undergoing lumbar laminectomy and/or osteosynthesis into two groups of 30 patients each. The control group (R-group) received only Ropivacaine (150 mg of Ropivacaine 7.5% (20 ml) added to 2 ml of normal saline in the wound infiltration), while the intervention group (RD-group) received Ropivacaine with the addition of dexamethasone (150 mg of Ropivacaine 7.5% (20 ml) added to 8 mg of dexamethasone in the wound infiltration). Both groups were administered patient-controlled analgesia (PCA) with morphine for self-medication. Postoperatively, a blinded evaluator assessed pain at H0, recorded the assessment of surgical scar pain using the Visual Analog Scale (VAS) at 4, 6, 12, 24, and 48 hours, as well as the time to the first opioid request, cumulative morphine consumption, opioid-related side effects, and length of stay. All patients were scheduled for a 3-month follow-up call to monitor chronic pain progression.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Ropivacaine 0.75% Injectable Solution

Trials testing the same drug.

Other recruiting trials for Lumbar Spinal Stenosis

Currently open trials in the same condition.

Other University Hospital Fattouma Bourguiba trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05871073.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing